Ligand Pharmaceuticals (LGND) Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Which has preferable earnings & valuation, LGND or ADMA?

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$167.13M	15.68	-$4.03M	-$7.12	-19.08
ADMA Biologics	$426.45M	10.08	$197.67M	$0.85	21.19

Does the media favor LGND or ADMA?

In the previous week, ADMA Biologics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 8 mentions for ADMA Biologics and 5 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat ADMA Biologics' score of 0.85 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, LGND or ADMA?

Ligand Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Is LGND or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Ligand Pharmaceuticals' net margin of -73.07%. ADMA Biologics' return on equity of 47.16% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	-73.07%	-7.83%	-6.92%
ADMA Biologics	45.01%	47.16%	30.51%

Do institutionals & insiders hold more shares of LGND or ADMA?

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts recommend LGND or ADMA?

Ligand Pharmaceuticals currently has a consensus price target of $147.17, suggesting a potential upside of 8.35%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 53.62%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks.